Aspirin Versus Clopidogrel in Prevention of Ischemic Stroke Recurrence: an Evaluation of Effectiveness and Safety from Beijing Medical Insurance Database

L. Yang,L. Wen,J. Wu
DOI: https://doi.org/10.1016/j.jval.2016.03.075
IF: 5.156
2016-01-01
Value in Health
Abstract:To evaluate the effectiveness and safety of aspirin and clopidrogel in prevention of ischemic stroke (IS) recurrence from data of Beijing medical insurance database. We randomly selected 10% of patients diagnosed as IS at the first time during January 2012- December 2012 and then followed their inpatient records and prescription records to September 2013 from Beijing urban employees and residents medical insurance database. Patients were selected and then categorized into two groups based on whether they received aspirin or clopidogrel. The primary end point for effectiveness was the readmission rate due to IS recurrence and for safety was the rate of hemorrhage events, Data of demographic characteristics, outpatient treatment, utilization of anticoagulant drugs and comorbidities were controlled in logistic regression analysis with stata12.0. 3149 IS patients (male 64.59%) with average age 67.37 (±13.90) years old were included in our study. In aspirin group, 2370 patients (male 62.87%) were included with average age 68.03(±14.03) years and in clopidogrel group 779 patients (male 69.96%) were included with average age 65.34(±13.29) years. The rate of IS recurrence was 47.68% in aspirin group and 52.25% in clopidogrel group. The rate of hemorrhage events was 1.73% in aspirin group and 2.82% in clopidogrel group. The difference of IS recurrence rate and hemorrhage events in two groups was not significant when controlling other confounding factors. We didn’t observe significant difference of recurrence and hemorrhage events for IS patients between aspirin or clopidogrel utilization.
What problem does this paper attempt to address?